Skip to main content

Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.

Publication ,  Journal Article
Friedman, HS; Colvin, OM; Skapek, SX; Ludeman, SM; Elion, GB; Schold, SC; Jacobsen, PF; Muhlbaier, LH; Bigner, DD
Published in: Cancer Res
August 1, 1988

A series of bifunctional alkylators were tested against the genotypically and phenotypically heterogeneous continuous human medulloblastoma cell lines, TE-671, Daoy, and D283 Med in vitro and against TE-671 and Daoy growing as s.c. and intracranial xenografts in athymic mice. Drugs tested included melphalan, cyclophosphamide, iphosphamide, phenylketocyclophosphamide, thiotepa, 1,3-bis(2-chloroethyl)-1-nitrosourea (in vivo), and busulfan (in vivo). Melphalan and phenylketocyclophosphamide were the most active agents in vitro with drug doses at which there is a 90% reduction in the number of colonies in comparison to controls of 2.13, 5.29, and 4.72 microM for melphalan and 4.60, 5.01, and 4.34 microM for phenylketocyclophosphamide against TE-671, D283 Med, and Daoy, respectively. Melphalan, cyclophosphamide, iphosphamide, phenylketocyclophosphamide, and thiotepa produced significant growth delays against s.c. TE-671 and Daoy xenografts, while no activity could be demonstrated for 1,3-bis(2-chloroethyl)-1-nitrosourea or busulfan. Melphalan, cyclophosphamide, iphosphamide, and thiotepa also produced significant increases in median survival in mice bearing intracranial TE-671 and Daoy xenografts. These results extend our previous studies demonstrating the antitumor activity of nitrogen and phosphoramide mustard-based bifunctional alkylating agents in the treatment of human medulloblastoma continuous cell lines and transplantable xenografts, and support the continued use of these agents in clinical trials.

Duke Scholars

Published In

Cancer Res

ISSN

0008-5472

Publication Date

August 1, 1988

Volume

48

Issue

15

Start / End Page

4189 / 4195

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasm Transplantation
  • Mice, Inbred BALB C
  • Mice
  • Medulloblastoma
  • Male
  • Humans
  • Female
  • Dose-Response Relationship, Drug
  • Cross-Linking Reagents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Friedman, H. S., Colvin, O. M., Skapek, S. X., Ludeman, S. M., Elion, G. B., Schold, S. C., … Bigner, D. D. (1988). Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res, 48(15), 4189–4195.
Friedman, H. S., O. M. Colvin, S. X. Skapek, S. M. Ludeman, G. B. Elion, S. C. Schold, P. F. Jacobsen, L. H. Muhlbaier, and D. D. Bigner. “Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents.Cancer Res 48, no. 15 (August 1, 1988): 4189–95.
Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC, et al. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res. 1988 Aug 1;48(15):4189–95.
Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC, Jacobsen PF, Muhlbaier LH, Bigner DD. Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res. 1988 Aug 1;48(15):4189–4195.

Published In

Cancer Res

ISSN

0008-5472

Publication Date

August 1, 1988

Volume

48

Issue

15

Start / End Page

4189 / 4195

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • Neoplasm Transplantation
  • Mice, Inbred BALB C
  • Mice
  • Medulloblastoma
  • Male
  • Humans
  • Female
  • Dose-Response Relationship, Drug
  • Cross-Linking Reagents